MX2010012358A - Tratamientos para el mieloma multiple. - Google Patents

Tratamientos para el mieloma multiple.

Info

Publication number
MX2010012358A
MX2010012358A MX2010012358A MX2010012358A MX2010012358A MX 2010012358 A MX2010012358 A MX 2010012358A MX 2010012358 A MX2010012358 A MX 2010012358A MX 2010012358 A MX2010012358 A MX 2010012358A MX 2010012358 A MX2010012358 A MX 2010012358A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
cells
acceptable salt
treatment
multiple myeloma
Prior art date
Application number
MX2010012358A
Other languages
English (en)
Spanish (es)
Inventor
Enrique Ocio
Atanasio Pandiella
Jesus San Miguel
Manuel Avila S Mara N Pablo
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2010012358A publication Critical patent/MX2010012358A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010012358A 2008-05-16 2009-05-18 Tratamientos para el mieloma multiple. MX2010012358A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08380154 2008-05-16
PCT/EP2009/055978 WO2009138509A1 (en) 2008-05-16 2009-05-18 Multiple myeloma treatments

Publications (1)

Publication Number Publication Date
MX2010012358A true MX2010012358A (es) 2011-01-25

Family

ID=40848780

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012358A MX2010012358A (es) 2008-05-16 2009-05-18 Tratamientos para el mieloma multiple.

Country Status (12)

Country Link
US (1) US8435992B2 (OSRAM)
EP (1) EP2303274A1 (OSRAM)
JP (1) JP2011520846A (OSRAM)
KR (1) KR20110028454A (OSRAM)
CN (1) CN102065865B (OSRAM)
AU (1) AU2009248039B2 (OSRAM)
CA (1) CA2724206A1 (OSRAM)
IL (1) IL209360A (OSRAM)
MX (1) MX2010012358A (OSRAM)
NZ (1) NZ589270A (OSRAM)
RU (1) RU2519750C2 (OSRAM)
WO (1) WO2009138509A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
WO2009140675A2 (en) * 2008-05-16 2009-11-19 Pharma Mar, S.A. Combination therapy with an antitumor alkaloid
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
KR101471273B1 (ko) * 2013-01-29 2014-12-11 인제대학교 산학협력단 Ｓｏｄ２를 포함하는 보르테조밉 내성 진단용 바이오 마커 조성물 및 이를 이용한 진단 키트
KR101718800B1 (ko) 2015-01-21 2017-03-24 주식회사 디알나노 약물 및 ｓｉＲＮＡ의 공동―운반용 나노복합체 및 이의 용도
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074243C (zh) * 1997-09-16 2001-11-07 林禾杰 对虾养殖方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US6569859B1 (en) * 2000-02-22 2003-05-27 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0229793D0 (en) * 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
WO2004080477A1 (en) * 2003-03-12 2004-09-23 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a

Also Published As

Publication number Publication date
US20110076343A1 (en) 2011-03-31
KR20110028454A (ko) 2011-03-18
RU2010151660A (ru) 2012-06-27
CN102065865A (zh) 2011-05-18
JP2011520846A (ja) 2011-07-21
AU2009248039B2 (en) 2014-07-31
NZ589270A (en) 2011-12-22
AU2009248039A1 (en) 2009-11-19
RU2519750C2 (ru) 2014-06-20
CN102065865B (zh) 2013-03-20
EP2303274A1 (en) 2011-04-06
IL209360A (en) 2015-10-29
IL209360A0 (en) 2011-01-31
CA2724206A1 (en) 2009-11-19
US8435992B2 (en) 2013-05-07
WO2009138509A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
MX2010012358A (es) Tratamientos para el mieloma multiple.
JP6905075B2 (ja) 腫瘍の治療または予防のための併用療法
EP2694072B1 (en) Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
JP2018109036A (ja) 改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ
US20190269663A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
HK1251162A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
CN102421429A (zh) 癌症治疗用选择性ep4受体拮抗物质
TW201919612A (zh) 包含帕博西尼（ｐａｌｂｏｃｉｃｌｉｂ）及６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧基苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－甲酸的組合
EP2049121B1 (en) Compositions for promoting activity of anti-cancer therapies
JP2023502742A (ja) Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
JP2022508935A (ja) がん治療における免疫モジュレーションのための組合せ
EP2670405B1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
US8569280B2 (en) Methods for the treatment of multiple myeloma
JP6748704B2 (ja) 抗癌治療剤
KR20220123033A (ko) 암 치료 방법 및 의약
CN108703968B (zh) 左旋千金藤啶碱用于抑制或治疗转移性乳腺癌的用途
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
EP4257132A1 (en) Sik3 inhibitors for treating diseases resistant to death receptor signalling
US20190365680A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
JP6629753B2 (ja) がん治療剤の組合せ
CN115227695A (zh) 包含靶向治疗剂的联合疗法
CN108299390A (zh) 抗肿瘤化合物dcz0415及其制备方法和应用
US20230181593A1 (en) Compositions and methods for treating breast cancer
WO2024220839A1 (en) Methods of treating hepatic-only metastatic uveal melanoma
WO2024088392A1 (zh) 用于治疗肿瘤的药物组合、药物组合物及其用途

Legal Events

Date Code Title Description
FG Grant or registration